Journey Medical Corporation announced the publication of results from a Phase 1 clinical trial evaluating the impact of Emrosi™ (DFD-29), a low-dose oral minocycline, on the skin, gastrointestinal, and vaginal microflora in healthy adults. The results were published in the Journal of Drugs in Dermatology. The trial achieved all primary objectives, demonstrating that 16 weeks of Emrosi administration had no detectable effects on normal microbiota and was well tolerated, with no significant safety issues reported. The findings support the use of Emrosi as a therapeutic option for moderate-to-severe rosacea. The clinical trial results have already been presented through publication.